U-698-M

Cat.No.: CSC-C0101

Species: Homo sapiens (Human)

Morphology: single or clumped cells in suspension; some cells adhere to plastic

Culture Properties: suspension

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C0101

Description

Established from the involved tonsil of a 7-year-old boy with lymphoblastic lymphoma at diagnosis prior to therapy in 1972; cells were described to be EBV-negative

Species

Homo sapiens (Human)

Recommended Medium

90% RPMI-1640 + 10% h.i. FBS

Culture Properties

suspension

Morphology

single or clumped cells in suspension; some cells adhere to plastic

Karyotype

Human hyperdiploid karyotype with 5.5% polyploidy - 49(44-50)<2n>XY, +3, +7, -14, +mar, dup(1)(q43q21.2), der(2)t(2;3)(p16;p11), add(3)(p11), del(6)(q15q22), del(9)(p22), dup(11)(q23q13), add(13)(p12), add(16)(q24) - carries large submetacentric dup(1) ma

Disease

Lymphoblastic Lymphoma

Quality Control

Mycoplasma: negative in DAPI, microbiological culture assays
Immunology: CD3 -, CD10 +, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, CD38 +, CD138 -, HLA-DR +, sm/cyIgG -, sm/cyIgM +, sm/cykappa +, sm/cylambda -
Viruses: ELISA: reverse transcriptase negative;

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 6 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Synonyms

U-698 M; U-698M; U698-M; U698M; U-698; U698

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The U-698-M cell line is a human B-cell lymphoma cell line established in 1972 from the involved tonsil of a 7-year-old male patient diagnosed with lymphoblastic lymphoma before any therapeutic intervention. It is genetically hyperdiploid (modal number 49; range 44-50) and EBV negative.

Morphologically, the cells are lymphoblast-like, growing in suspension as single cells or small clumps, with a minority loosely adhering to the plastic surface. They have mature B cell immunophenotype, and are positive for CD10, CD19, CD20, CD37, CD38, HLA-DR and surface IgM (smIgM) and negative for CD3 and CD34. The U-698-M cells are grown under standard conditions (37°C, 5% CO₂) in a nutrient-rich basal media fortified with serum. These cells have a doubling time of ~48 h and are sub-cultured by seeding at 0.5 × 10⁶ cells/mL and splitting at a ratio of 1:2 to 1:5 every 2-3 days.

U-698-M cells are frequently used as a model system for the study of B-cell lymphomagenesis, immune cell signaling pathways, and for screening of targeted therapies and immunological reagents in hematologic malignancy research due to their unique B-lineage properties and genetic stability.

Neoantigen-Specific TCRs Display In Vivo Antitumor Potential

Neoantigens generated by somatic mutations are promising targets for personalized immunotherapy, but the association between TCR functionality and in vivo efficacy remains to be further characterized. Bräunlein et al. examined neoantigen-specific TCRs in a detailed case study of metastatic melanoma using a xenograft model.

U-698-M lymphoma cells transduced with minigene (MG) constructs encoding defined neoantigens were injected subcutaneously into NSG mice. Next, they evaluated the antitumor activity of four neoantigen-specific TCRs (SYTL4-TIL1, SYTL4-PBC1, KIF2C-PBC1, KIF2C-PBC2) versus a control TCR (2.5D6).

TCR-transduced T cells were given intravenously. Control TCR recipients exhibited progressive tumor growth, while mice treated with neoantigen-specific TCRs completely rejected the tumor (Fig. 1A). Importantly, KIF2C-PBC1 (~14% transduction efficiency) and KIF2C-PBC2 (~62%) induced strong kinetics of rejection. Survival analysis confirmed that neoantigen-specific TCRs significantly prolonged survival compared to the control cohort euthanised for ulcerating tumor burden (Fig. 1B). Flow cytometry showed that TCR-transgenic T cells efficiently infiltrated the tumors by day 4 and were still detected in the spleen, bone marrow and blood at day 20 (Fig. 1C). These data indicate that neoantigen-specific TCRs can induce potent and durable antitumor immunity, independent of small differences in transduction efficiency.

Performance of T cells transgenic for neoantigen-specific TCRs in vivo. — Fig. 1. Performance of T cells transgenic for neoantigen-specific TCRs *in vivo* (Bräunlein E, Lupoli G, *et al.*, 2021).

Ask a Question

Write your own review

You May Also Need

CM-1448Y

SuperCult® RPMI 1640 Medium

INQUIRY

CS-001Y

PremSera® FBS

INQUIRY

WILL-1

Description: Established in 2007 from the bone marrow mononuclear cells of an 82-year-old Japanese man with diffuse large B-cell lymphoma in the leukemic phase

Cat#: CSC-C0633 INQUIRY

View Product

TALL-1

Description: Established from the bone marrow of a 28-year-old man who developed the terminal leukemic phase of lymphosarcoma in 1976

Cat#: CSC-C0530 INQUIRY

View Product

KG-1

Description: This cell line was derived from the bone marrow aspirate of a 59 year old male with erythroleukemia that became acute myelogenous leukaemia.The cells form colonies in soft-agar in the presence of ...

Cat#: CSC-C8220L INQUIRY

View Product

L-82

Description: Established from the pleural effusion of a 24-year-old woman with recurrent anaplastic large cell lymphoma (ALCL); cells were described to clonally derive from T-lineage lymphoid cells and to be ...

Cat#: CSC-C0600 INQUIRY

View Product

SUP-HD1

Description: Established from a 37-year-old man at second (refractory/terminal) relapse of Hodgkin lymphoma (nodular sclerosing -> lymphocyte depleted/stage IIISA -> stage IV) after both combined chemo- and ...

Cat#: CSC-C0579 INQUIRY

View Product

MHH-CALL-4

Description: Established from the peripheral blood of a 10-year-old Caucasian boy with acute lymphoblastic leukemia (pre B-ALL) at diagnosis in 1993

Cat#: CSC-C0396 INQUIRY

View Product

For research use only. Not for any other purpose.